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Abstract
Objective
Studies on children with Acute Lymphoblastic Leukemia (ALL) reported non-adherence in
2–54% of cases. The primary objective of this study was to assess rates of adherence to 6-
MP using two different methods in children and adolescents with ALL. Secondary aim was
to identify factors that influence adherence to 6-MP in children with ALL.
Methods
All eligible children with ALL who are ( 19) years old and receive 6-MP therapy for at least
1 month were approached to participate in the study. A total of 52 children with ALL and their
primary caregivers were recruited. Adherence measures included an objective method
(measuring 6-MP metabolites in packed Red Blood Cells (RBCs)) and a subjective method
(using parent and child self-report via the Medication Adherence Report Scale; MARS;
Adherence was defined as 90% or greater).
Results
Rates of adherence varied across the measurement methods. Packed RBCs sample analy-
sis indicated forty-four patients (84.6%) to be adherent. Using the MARS questionnaires, a
total of 49 children (94.2%) were classified as being adherent according to the parental
MARS questionnaire scores, while all the 15 children (100%) who answered the MARS
(child) questionnaire were classified as adherent. Overall adherence rate was 80.8% within
the studied population.
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Conclusion
MARS scale was shown to overestimate adherence compared to measurement of 6-MP
metabolites in the blood. A combination of both methods led to increased detection of non-
adherence to thiopurine in children with ALL.
Introduction
Acute lymphoblastic leukemia (ALL) is the most common cancer in children[1]. Maintenance
therapy in ALL consists of daily doses of 6-mercaptopurine (6-MP), weekly methotrexate
interrupted by monthly pulses of vincristine and dexamethasone[2]. 6-MP is considered the
most easily monitored treatment due to its daily administration and stable intracellular metab-
olites[3]. 6-MP is a drug with cytotoxic effects that has a short half-life (1.5 hours), so measur-
ing its plasma level cannot be used to assess drug effect. However, intracellular accumulation
of 6-MP metabolites [6-thioguanine (6-TGN) and 6-methyl mercaptopurine (6-mMPN)]
occurs over a period of 2–3 weeks; measuring the concentration of the metabolites is essential
in therapeutic drug monitoring and considered as a good indicator of long term adherence[4].
6-TGN is considered the most active thiopurine metabolite[5], while 6-mMPN is considered
responsible for the side-effects of thiopurine therapy[6]. Measuring 6-MP metabolite levels in
blood or urine provide an objective measure of adherence to medication; however, this meth-
odology can be expensive and is not always available [3]
Poor adherence to medication treatment is a recognised problem in paediatric patients,
where non-adherence rates are reported to range from 25% to 60% [7–10]. Since paediatric
ALL patients become practically asymptomatic once remission is attained, but continue to
require complex treatment, non-adherence to prescribed treatment in ALL patients is
expected[11]. Studies in children and adolescents with ALL reported non-adherence to 6-MP
in 17–46% of the cases [3,12–14]. This problem has several negative consequences such as
repeated clinic visits, extended course of illness, poorly controlled symptoms and increased
cost due, for example, to unnecessary hospital admissions[15]. Therefore, non-adherence is a
significant concern in all illnesses especially in patients with chronic conditions, including
children.
There is no standard limit for what constitutes adequate adherence, with some trials consid-
ering adherence rates > 95% as being essential. [16]. Different methods of adherence assess-
ment have been reported including prescription refills, pill counts, electronic monitors built
into medication containers, blood levels of the drug, patient self-report and physician evalua-
tion of patient adherence [17,18]. However, there are no methods without methodological lim-
itations[19].
Reports on non-adherence to oral 6-MP have relied on small cohorts of patients and been
based largely on self-report [13,20–23]. However, this approach can be susceptible to misrepre-
sentation and may overestimate a patient’s adherence [17,18,24]. Using cutt-off point limits
for assessing adherence to 6-MP (using blood levels) is susceptible to bias due to high variabil-
ity of drug concentration in patients even if they receive the same dose. Therefore, hierarchical
cluster analysis of drug metabolite concentrations (which was used in this study) is a good
approach as an objective method to assess non-adherence to 6-MP [3]. The use a multi-
method approach (at least two adherence measurement sources) for assessing adherence is rec-
ommended to increase reliability of detecting non-adherence [3].
The rate of non-adherence to 6- MP is reliably unknown in children with ALL. This study
is the first to evaluate adherence to 6-MP using two measurement methods in Jordan (blood
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level determinations using hierarchical cluster analysis, and via patient and parent self-report).
Secondary aim was to identify factors that influence adherence to 6-MP in children with ALL
Methods
2.1 Study subjects, setting and data collection
The study was approved by the research Committees (IRB) in King Hussein Cancer Centre
(KHCC), Amman-Jordan (Reference number: 15KHCC 57). Recruitment of study subjects
occurred over the period from September, 2015 to September, 2016. Informed parental con-
sent was obtained for each child before enrolment in the study. In addition, verbal assent was
obtained from older children (>6 years) after provision of a verbal description of the study
and what it involved. All eligible patients and their parent were approached (n = 53) and only
one parent refused to participate with his child in the study. Data were collected prospectively
from paediatric patients (19 years) (n = 52) attending the Outpatient Paediatric Leukemia
Clinic at KHCC and who had been receiving continuous/maintenance 6-MP therapy for at
least 1 month. Children at KHCC are treated based on the St. Jude total XV and total XIII pro-
tocols[25,26]. According to this approach, the continuation phase consists of 120 weeks for
females and 146 weeks for males. In this phase, patients receive different chemotherapeutic
agents with different dosing regimens including 6-MP, high dose and low dose methotrexate,
vincristine, dexamethasone and asparaginase depending on the risk category of the patient.
Post week 24 of the continuation phase, all patients are maintained on the same dose of 6-MP
(75mg/m2/day) daily until the end of treatment. The dose of 6-MP is modified (increased or
decreased) if the patient has a persistently high acute neutrophil count or if the patient has
recurrent toxicities (myelosuppression) respectively. 6-MP is administered in the evening on
an empty stomach. Patients who had appointments in the leukemia clinic were identified, and
were considered for study inclusion if they were in the continuation phase post week 24 of
treatment and if they had been maintained on 6-MP for at least 1 month. If 6-MP was stopped
for more than 3 days, patients were excluded.
Once a patient was recruited, data were obtained from their clinical files, which included
demographic data, medical history, biochemical data (complete blood count and liver function
tests), and information relating to side-effects of 6-MP (elevated liver enzymes, neutropenia).
Whole blood samples (one sample per patient; 2 mL aliquot) were taken from a routine clini-
cal blood sample withdrawn from the child at the clinic. All the blood samples were labeled with
the patient study number together with the date and time of collection. Blood samples were col-
lected by a research assistant and processed within 4 hours of taking the sample.
The Arabic translated and validated version of Medication Adherence Report Scale (MARS)
[27] was completed by parents and by older children ( 11 years). The parent’s version con-
sisted of six questions; mean scores were summed to give a scale score ranging from 1 to 5.
The child’s version consisted of five items; mean scores were summed to give a scale score
ranging from 1 to 5. Higher scores indicate higher levels of self-reported adherence. In the
present study, 90% cut-off points for adherence were used, i.e. a participant was considered to
be adherent, if the parental/ child MARS score was at least 4.5 out of 5. This cut-off point was
selected to represent situation where even relatively fluctuations in adherence may be clini-
cally significant.
2.2 Analysis of blood samples
All venous blood samples obtained from patients at the clinic visit were processed into plasma
and packed red blood cell (RBC) samples and stored at -80˚C prior to analysis at the Pharma-
ceutical Research Center, Jordan university of Science and Technology.
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A sensitive, selective, microanalytical method for determination of the 6-MP metabolites in
packed RBCs was developed and validated (S1 Appendix). The method utilized 100 μl of
packed RBCs. The sample preparation step involved the addition of 100 μl dithiothreitol (75
mg/mL) to the 100 μl of packed RBCs and 150 μl of water. The sample was vortexed for 1 min-
ute after which 50 microlitres of perchloric acid (700 mL/L) was added and vortex-mixed for a
further 30 seconds. The sample was then centrifuged at 13,000 × g for 15 minutes at 4˚C, and
all the clear supernatant layer was removed and heated for 45 min on 100˚C using a heating
block. After cooling, 700 µL of water was added and the solution vortex-mixed for 10 seconds
before being transferred to MCX solid phase extraction (SPE) cartridges (1 ml/30 g; Waters).
The sample mixture was then dried under a stream of nitrogen at 37˚C for 20 min and recon-
stituted in 100 µL 0.05 M NaOH with vortex-mixing for 1 minute. Samples were analyzed
using high-performance liquid chromatography (HPLC) with UV detection (322nm and at
342 nm). The assay limits of quantification for 6-TGNs and 6-mMPNs were 0.5 and 3.75 μM,
respectively. All inter- and intra-day accuracy and precision measures obtained were satisfac-
tory according to the Food and Drug Administration guideline (±15%) [28] ranged from
−7.0% to 12.62%. Concentration ranges covered by the assay validation were 0.5–20μM for
6-TGNs and 3.75–300μM for 6-mMPNs.
2.3 Study measures and adherence assessment
Adherence to 6-MP was assessed using levels of 6-MP metabolites in packed RBCs and results
from parent and child self-report using the MARS questionnaires (Table 1).
The correlation between the concentrations of both metabolites was studied [3,29]. Patients
were clustered into four categories according to their 6-TG and 6-mMPNs levels. Cluster A
(i.e. above 20th percentile cutoff point) was characterized by high levels of 6-TGN levels and
6-mMP levels (positive correlation) thus patients were considered adherent to medication.
Cluster B was characterized by negative correlations between the two metabolites (high levels
of 6-mMP but with low 6-TGN concentrations), it is expected that those patients had higher
TPMT activity which shift 6-MP metabolism toward 6-mMP production. Cluster C was char-
acterized by low levels of both 6-mMP levels and 6-TGN (non-adherent patients, i.e. less than
20th percentile cutoff point). Cluster D patients have also (negative correlations between the
two metabolites) low levels of 6-mMP levels and high levels of 6-TGN, it is expected that those
patients had lower TPMT activity which shift 6-MP metabolism toward 6-TG production.
2.4 Data analysis
Descriptive statistics (mean and standard deviation (SD) for continuous data, number (N)
and percentage (%) for categorical data) were used to describe participants’ demographic
Table 1. Classification of medication-adherence using different measures.
Adherence measure Type of
measure
Adherent Non-adherent
TGNs and 6-mMPs levels in
packed RBCs
Objective Concentrations of both 6-TGN and 6-mMP above
a threshold value*
Concentrations of both 6-TGN and 6-mMP below
a threshold value
MARS**(parent/caregiver) Subjective If MARS mean score is  4.5 If MARS mean score is <4.5
MARS (child) Subjective If MARS score is 4.5 If MARS mean score is <4.5
* (20th percentile) of 6-TGNs and 6-mMPNs levels
** MARS: Medication Adherence Report Scale
https://doi.org/10.1371/journal.pone.0183119.t001
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characteristics, disease characteristics and adherence. If continuous variables were not nor-
mally distributed, median and range were used. Cluster analysis, using the 20th percentile
as a cutoff point, was used to investigate the pattern of 6-TGN and 6-mMP metabolite con-
centrations in patients with ALL and to group these patients according to their metabolite
levels.
Factors that were linked to adherence to 6-MP treatment were identified using the data
obtained from the patients’ medical notes and demographic characteristics. Group differences
(adherent and non-adherent) were explored using Mann Whitney U test for continuous vari-
ables. Categorical variables were analyzed using Chi-squared analysis. If the expected fre-
quency fell below 5, the Fisher’s exact test was employed. All analyses were carried out using
SPSS1 software version 22. The significance level was set at 0.05.
Results
3.1 Patients and disease characteristics
Fifty-two eligible patients and their primary caregivers/parents (n = 52) were approached and
agreed to take part in this cross-sectional study. The demographics and disease characteristics
of the study sample are described in Table 2. Thirty-one patients were male (59.6%) with the
mean age of 8.9 years (SD = 4.4). On the other hand, 10 parents were males (19.2%) with the
mean age of 36.2 years (SD = 7.4).
The mean duration of illness was 1.73 years (SD = 1.61). The number of medications
received by patients ranged from 2–7 medications (median = 3) [Data was not normally
distributed].
3.2 Adherence assessment
3.2.1 6-MP metabolite concentrations in plasma and packed RBC samples. A total of
52 venous blood samples (processed into packed RBCs) were obtained from the 52 study
patients. Both 6-TGN and 6-mMP metabolite concentrations were measured for all study sub-
jects. Based on cluster analysis [3], patients were segregated according to their adherence;
forty-four patients (n = 44, 84.6%) were considered adherent and 8 children were classified as
non-adherent (15.4%) Fig 1.
3.2.2 Adherence using MARS-specific (parent and child versions). Score distribution
for the MARS questionnaires is presented in Table 3. Children were classified as being adher-
ent if the total score was greater than or equal to the 90th percentile of the maximum score (i.
e 4.5 for MARS (parent and child)). Accordingly, using the parental total MARS question-
naire scores, a total of 49 children (94.2%) were classified as being adherent. On the other
hand, among the 15 children who answered the MARS (child) questionnaire (those aged 11
years or above), all children (100%) were classified as being adherent.
3.3 Comparison between different methods of adherence assessment
Packed RBCs sample analysis captured the highest percentage of non-adherence (15.4%) fol-
lowed by the MARS (parent) questionnaire (5.8%). MARS (child) questionnaire did not iden-
tify any non-adherence (0.0%). Combination of these assessment approaches (classified as
non-adherent if either method identified patient as non-adherent) resulted in an overall non-
adherence rate of 19.2%.
The level of agreement between the packed RBCs and the MARS (parent) methods was
found to have Kappa = 0.107 (p-value = 0.375, 95% CI = -0.204–0.438).
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3.4 Factors affecting overall adherence to 6-MP
An investigation of the factors affecting adherence to 6-MP in children with ALL was per-
formed. None of the studied factors (child age, parent age, child gender, parent gender, parent
educational level, duration of ALL treatment, number of medications, and the presence of side
effects) were found to affect adherence (p>0.05), therefore a multivariate analysis was not
conducted.
Discussion
This is the first study in Jordan that investigated the adherence to 6-MP in children and adoles-
cents with ALL utilizing an objective method (measuring 6-MP metabolites in packed RBCs)
as well as a subjective method (self-reported questionnaires) to determine non-adherence to
6-MP treatment. Since non-adherence is potentially life threatening in children with ALL, a
Table 2. Demographic and disease characteristics of the study sample (n = 52)*.
Parameters Results
Patient’s age (years) 8.9 (4.4)
Patient’s gender, n(%)
■ Males
■ Females
31 (59.6)
21 (40.4)
Patient’s weight (kg) 33.4 (20.8)
**Parents age (years) 36.2 (7.4)
**Parents gender, n (%)
■ Males
■ Females
10 (19.2)
42 (80.2)
Disease duration(years) 1.73 (1.61)
6-MP daily dose (mg/m2), median (range) 66.59 (44.6–107.9)
6-MP daily dose (mg/kg), median (range) 2.23 (1.05–3.18)
Metabolite concentrations
6-TGNs (μM), median (range) 4.2 (undetectable–10.6)
6-mMPNs (μM), median (range) 52.58 (undetectable–123.9)
Number of medications, n (%)
■ 2
■ 3
■ 4
■5
5 (9.6)
23 (44.2)
14 (26.9)
10 (19.2)
Presence of side effects, n (%)
■ Yes 11 (21.2)
Type of side effect, n (%)
■ Decrease ANC
■ Elevation ANC
■ Hepatic toxicity
■ Neutropenia
■ Severe MTX neurotoxicity
■ Hyperbilirubinemia
■ Hypersensitivity to 6-MP
2 (3.8)
3 (5.8)
1 (1.9)
2 (3.8)
1 (1.9)
1 (1.9)
1 (1.9)
*Data presented as mean (SD) unless otherwise stated
** Parents who filled out the MARS questionnaire.
SD: Standard deviation
ANC: Absolute neutrophil count
MTX: Methotrexate
https://doi.org/10.1371/journal.pone.0183119.t002
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multi-method approach for assessing adherence is an appropriate way of increasing sensitivity
and reliability in detecting non-adherence[3].
Adherence to prescribed treatment is a complex and multi-factorial matter that is poorly
understood[30]. It is a key element for the evaluation of treatment efficacy and safety, thus
Fig 1. Scatter plot showing the four different clusters formed after hierarchical clustering of the ALL study sample using 20th percentile
of metabolite levels as cutoff point. Data for 6-mMPNs and 6-TGNs are the metabolite levels (adjusted per dose/SA). Cluster A (i.e. above 20%
cutoff point) was characterized by high levels of 6-TGN levels and 6-mMP levels (adherent patients). Cluster B was characterized by high levels of
6-mMP but with low 6-TGN concentrations, it is expected that those patients in Cluster B had higher TPMT activity than those in cluster A, which
would explain the shift in 6-MP metabolism toward 6-mMP production in those patients. Cluster C was characterized by low levels of both 6-mMP
levels and 6-TGN (non-adherent patients). Cluster D patients have low levels of 6-mMP levels and high levels of 6-TGN (Lower TPMT activity in
patients in Cluster D compared to those in cluster A would explain the shift in 6-MP metabolism toward 6-TG production in those patients).
https://doi.org/10.1371/journal.pone.0183119.g001
Table 3. Distribution of the total scores for the MARS questionnaires reported by participating parents and children.
Measure n Total score mean Total score range Number (%) of non-adherent patients (score < 4.5)
MARS* (Parent) 52 4.8 4.3–5 3 (5.8%)
MARS* (Child) 15 4.9 4.6–5 0(0%)
* MARS: Medication Adherence Report Scale
https://doi.org/10.1371/journal.pone.0183119.t003
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adherence plays an important role in clinical research and practice. The use of different ways
in assessing adherence decreases bias associated with using a single method[31–33].
The Arabic version of the MARS-specific questionnaire [27] was the self-report question-
naire used for adherence assessment in the present study. The majority (94.2%) of parents of
ALL patients reported that their children were adherent to their 6-MP treatment, while none
of the patients reported being non-adherent to 6-MP. This is consistent with the reported
overestimation of adherence using this method [34–37].
The objective measure utilized in the present study included clustering patients according
to their 6-MP metabolite concentrations (hierarchical cluster analysis). A 20th percentile cut-
off point for both metabolites was used to identify non-adherence to therapy. The idea of clus-
ter analysis regarding 6-MP active metabolites has been applied in two previous studies [3,29].
Traore et al used this method to identify patients at risk of suboptimal 6-MP therapy [29],
while Hawwa et al used it as a novel approach to assess non-adherence to oral thiopurines [3].
Upon the application of the objective method, eight ALL patients (15.4%) were considered
non-adherent to medication. These patients had their 6-mMPNs and 6-TGNs located within
cluster C in Fig 1 which represented low or undetectable levels of the metabolites (Fig 1).
The intracellular metabolism of 6-MP depends on the activity of thiopurine-S-methyltrans-
ferase enzyme (TPMT) which is subjected to genetic polymorphism with an inverse correlation
between 6-TGNs levels and TPMT activity[38]. It is reported that the concentrations of 6-MP
metabolites are subjected to large inter-individual variations[39].Unfortunately, information on
patient genotypes as TPMT testing is not used in the hospital. Having access to the latter infor-
mation can help differentiate patients who are received suboptimal 6-MP doses (Cluster B and
D). It is expected that those patients in Cluster B had higher TPMT activity than those in cluster
A, which would explain the shift in 6-MP metabolism toward 6-mMP production in those
patients. Lower TPMT activity in patients in Cluster D compared to those in cluster A would
explain the shift in 6-MP metabolism toward 6-TG production in those patients.
The objective method (RBC metabolite concentrations) was more effective in identifying
non-adherent patients (8 patients, 15.4%) than the subjective, parental self-report approach (3
patients, 5.8%) while the child self-report approach did not identify any cases of non-adher-
ence. Interestingly, two of the three patients identified as non-adherent using parental self-
report (MARS-specific) were not identified using the metabolite data. This could represent
good adherence in the period coming up to the clinic attendance (acute adherence) and high-
lights the importance of using a multi-method approach within this challenging field. When
both methods were combined a total of 10 patients were classified as non-adherent, i.e. overall
non-adherence was 19.2% which is similar to the reported range in international literature
[3,12–14,40–42]. In addition, those parents of non-adherent patients might not be involved in
giving the medication and children were responsible for taking the medication by themselves.
None of the factors studied (including patient age, parent age, patient gender, parent gen-
der, parent educational level, duration of ALL treatment, number of medications, and the pres-
ence of side effects) were found to be associated with patient adherence to 6-MP.
Unfortunately we were not able to identify factors affecting adherence in children patients
with ALL and this may be due to the small sample size however, this is the cohort in Jordan as
recruitment was conducted over one year and all eligible patients were approached and more
than 98% agreed to participate (52 out of 53 patients). In addition, other drivers of non-adher-
ence or false report of adherence (eg. sociodemographic status [22], parental beliefs about
medicines (BMQ), Patient’s and/or parent’s primary reasons for skipping medication doses
due to their busy schedules [43], RBC transfusions from a donor with high TPMT activity)
were not assessed in this research. These issues can be addressed in future studies with inclu-
sion of larger number of patients form different Arabic countries around Jordan.
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Limitations
The population of children with ALL investigated in the present study was relatively small,
however, it is larger than many cohorts of children and adolescents published thus far. Adher-
ence assessment was based on one blood sample for each patient; the inclusion of multiple
samples obtained at various time points may have resulted in a more accurate assessment of
adherence [39]. A further potential limitation of the study is that TPMT testing is not used in
Jordan. A major strength of the present study was the use of both objective and subjective mea-
sures for assessing adherence as this is one of the first studies to utilize an objective method to
measure adherence in ALL in Jordan.
Conclusion
In a serious, life threatening condition like ALL in children, one might expect full adherence
with curative medication. This obviously was not the case, even within healthcare system
where medications are made available. The study highlights the importance of using both sub-
jective and objective measures of adherence in identifying true adherence. The work highlights
the need for more robust education and monitoring programs for children and young people
with ALL, to help parents and patients better understand the disease and major benefits of
good adherence. The latter should be reinforced regularly with both parents and patients.
Supporting information
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